Biologics & mAb CDMOs — Ranked by Signal Score · 2026
· updated as new inspection, certificate, and trial data enters the platform
29
CDMOs tracked
29
Fully scored
15
With FDA records
45
FDA inspections
143
EMA/MHRA GMP certs
2
Warning letters
Biologics CDMOs manufacture monoclonal antibodies, fusion proteins, and other large molecules in mammalian (typically CHO) cell culture. It is the largest and most mature segment of contract manufacturing, spanning early clinical supply through multi-thousand-litre commercial production.
Selecting a biologics CDMO turns on bioreactor scale and modality fit (mAb, bispecific, fusion protein), titer and cell-line strategy, fill-finish, and — above all — a clean regulatory record at commercial scale. The rankings below score each CDMO on FDA inspection history, EMA/MHRA GMP certification, clinical-program activity, and capacity.
FDA inspection outcomes across these CDMOs: 14 NAI (no action), 29 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: United States (34), Italy (26), UNITED KINGDOM (25), Denmark (20), Germany (19).
Last updated 2026-10-06. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
PC
Pfizer CentreOne
Kalamazoo, MI · McPherson, KS
|
91.5 | 100.0 | 4 insp · 17 GMP | — | 366 programs |
| 2 |
MK
Merck KGaA / MilliporeSigma (CDMO)
Darmstadt, DE · St. Louis, MO
|
81.8 | 98.7 | 2 insp · 2 GMP | — | 22 programs |
| 3 |
FD
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
|
84.8 | 100.0 | 0 insp · 23 GMP | 0 programs | |
| 4 |
AJ
Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
|
83.5 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 5 |
PR
Piramal Pharma Solutions
Lexington, KY · Riverview, MI · Ahmedabad, IN
|
83.3 | 95.0 | 5 insp · 13 GMP | — | 0 programs |
| 6 |
RB
Richter BioLogics
Hamburg, Germany
|
82.9 | 100.0 | 0 insp · 9 GMP | — | 0 programs |
| 7 |
LB
Lotte Biologics
Incheon, KR · Syracuse, NY
|
81.6 | 100.0 | 1 insp · 0 GMP | — | 0 programs |
| 8 |
EF
Eurofins CDMO
Planegg, DE · San Diego, CA
|
81.6 | 100.0 | 5 insp · 0 GMP | — | 0 programs |
| 9 |
EK
Evonik Health Care
Birmingham, AL · Vancouver, BC
|
81.5 | 99.8 | 2 insp · 2 GMP | — | 0 programs |
| 10 |
CD
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
|
81.1 | 98.9 | 4 insp · 10 GMP | — | 0 programs |
| 11 |
AV
Avid Bioservices
Tustin, CA
|
80.8 | 100.0 | 1 insp · 0 GMP | — | 0 programs |
| 12 |
NW
Northway Biotech
Vilnius, LT; Waltham (MA), USA
|
80.8 | 100.0 | 0 insp · 8 GMP | Available | 0 programs |
| 13 |
BR
BioReliance (Merck)
Glasgow, UK · Rockville, MD
|
80.2 | 97.1 | 4 insp · 8 GMP | — | 0 programs |
| 14 |
CRA
Curia (RNA/Advanced)
Albany, NY · Albuquerque, NM
|
79.4 | 99.9 | 2 insp · 18 GMP | — | 0 programs |
| 15 |
Cytovance Biologics
Oklahoma City, OK
|
78.6 | 98.1 | 1 insp · 0 GMP | Available | 0 programs |
| 16 |
SG
Syngene International
Bengaluru, India
|
78.5 | 96.3 | 2 insp · 0 GMP | — | 0 programs |
| 17 |
PG
ProBioGen
Berlin, DE
|
78.1 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 18 |
PBI
ProBio
Taipei, Taiwan
|
78.1 | 100.0 | 0 insp · 9 GMP | — | 0 programs |
| 19 |
AF
Afton Scientific
Charlottesville, VA
|
76.8 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 20 |
KD
Kindeva Drug Delivery
Woodbury, MN
|
76.0 | 98.2 | 2 insp · 3 GMP | — | 0 programs |
| 21 |
BP
BSP Pharmaceuticals
Latina, Italy
|
70.5 | 83.6 | 7 insp · 14 GMP | — | 0 programs |
| 22 |
GM
Grand River Aseptic Manufacturing
Grand Rapids, MI
|
66.6 | 78.1 | 3 insp · 0 GMP | — | 0 programs |
| 23 |
SI
Simtra BioPharma Solutions
Bloomington, IN · Halle, DE
|
65.7 | 73.3 | 0 insp · 1 GMP | — | 0 programs |
| 24 |
AU
Aurigene Pharmaceutical Services
Hyderabad, India
|
63.0 | — | — | — | 0 programs |
| 25 |
HP
HIPRA Biotech Services
Amer, Spain
|
63.0 | — | — | — | 0 programs |
| 26 |
SS
Singota Solutions
Bloomington, IN
|
59.0 | — | — | — | 0 programs |
| 27 |
CU
Culture Biosciences
South San Francisco, CA
|
56.5 | — | — | — | 0 programs |
| 28 |
BT
BIOVECTRA
Charlottetown, PE, Canada
|
56.5 | — | — | — | 0 programs |
| 29 |
IC
INCOG BioPharma Services
Fishers, IN
|
56.5 | — | — | — | 0 programs |
What to evaluate in a Biologics / mAb CDMO
Scale & bioreactor fit
Match validated bioreactor scale (from a few hundred litres clinical to 2,000L+ commercial) and single-use vs stainless to your dose and indication. Confirm titer expectations for your construct.
Cell line & process development
Ask whether the CDMO offers its own expression platform/cell line or works from yours, and how process development and tech transfer are handled.
Regulatory track record
Biologics programs heading to BLA/MAA need a strong commercial-scale inspection history. Cross-check FDA 483s, warning letters, and EMA/MHRA GMP coverage — all shown above.
Drug substance to drug product
Confirm whether the CDMO covers fill-finish and formulation in-house or coordinates a separate site, which affects timelines and comparability.
Which biologics CDMOs handle mammalian vs microbial expression?
Biologics manufacturing splits along expression platform: mammalian (CHO, HEK) for monoclonal antibodies, Fc-fusions, and bispecifics; microbial (E. coli, Pichia) for smaller proteins, peptides, and some recombinant fragments. Most biologics CDMOs specialize in one platform; large diversified CDMOs like Lonza and Pfizer CentreOne run both. Individual CDMO profile pages flag platform coverage under the modality tags. Sponsors should confirm not just platform presence but validated batch scale and comparability data on the target expression system.
Commercial-scale biologics — who has the depth?
Commercial-scale biologics manufacturing requires validated production at 2,000L, 5,000L, and increasingly 20,000L single-use or stainless. The commercial-scale biologics filter surfaces CDMOs with top-quartile Signal Score or broad ClinicalTrials.gov footprint. Sponsors evaluating for BLA and commercial supply should verify recent FDA inspection classifications specifically on the biologics facility slated for their program — a Warning Letter on one site should not disqualify a CDMO with clean records elsewhere, but does require targeted diligence on the specific facility.
How to compare biologics CDMO quality records
The Quality Compliance pillar (35% of the composite) is the most decisive signal for biologics CDMO selection. Key components: recent FDA inspection classifications (NAI is clean, VAI indicates minor findings, OAI signals significant issues), Warning Letter history, and EMA and MHRA GMP certificate coverage. On individual CDMO profile pages, each 483 observation is dated and enumerated. Sponsors running a competitive bid should build a quality scorecard using these primary-source counts rather than relying on the CDMO's own summary — the underlying data is public and auditable.
How CDMO Signal computes the biologics ranking
The biologics Signal Score is the platform's standard four-pillar composite. Quality Compliance (35%) leans on FDA inspection classifications, Warning Letter history, and EMA/MHRA GMP density. Operations (25%) reflects ClinicalTrials.gov sponsor and program footprint. Financial Stability (20%) carries real weight for biologics specifically — this is a capital-intensive, long-cycle modality where parent-company health signals from SEC filings and M&A activity indicate whether a CDMO will be operationally reliable through a 3–5 year commercial engagement. Capacity Intelligence (20%) tracks monitored trade press for facility expansions. Full weightings at cdmosignal.com/methodology.
Bispecific antibody manufacturing — which CDMOs have the depth?
Bispecifics are the fastest-growing biologics segment, with distinct manufacturing challenges beyond standard mAb work: chain mispairing (managed via knob-in-hole, CrossMab, or DuoBody architectures), higher aggregation propensity requiring additional downstream steps, and specialized analytics for correct-pair confirmation. CDMOs with genuine bispecific depth typically have qualified purification trains beyond standard Protein A + polish, and have handled programs across at least two different bispecific architectures. Larger diversified CDMOs — Lonza, Samsung Biologics, WuXi Biologics, Boehringer Ingelheim — have led here; a subset of specialized CDMOs (KBI Biopharma, ProBioGen) are notable for engineering-heavy bispecific work. Sponsors should verify aggregate content specs at commercial scale and correct-pair confirmation via LC-MS or capillary IEF.
Biosimilar manufacturing — CDMO capabilities and regulatory pathway
Biosimilar manufacturing has a distinct regulatory profile: comparability to the reference product is the primary approval criterion, not novel efficacy demonstration. This creates specific CDMO requirements — analytical characterization depth (typically 30+ orthogonal methods), forced degradation programs, and Phase 3 comparability trial supply capability. CDMOs with biosimilar depth include Samsung Biologics (multiple approved biosimilars), Biocon Biologics, Celltrion (in-house + partner), Boehringer Ingelheim, Sandoz. Sponsors developing biosimilars should verify not just biologics capability but demonstrated regulatory pathway experience — specifically approved biosimilar filings under FDA 351(k) or EMA biosimilar pathway. Cost dynamics are also tighter than novel biologics; CDMOs experienced in this segment typically have cost-optimized workflows.
Single-use vs stainless steel — CDMO facility architecture matters
The choice between single-use bioreactor (SUB) systems and stainless steel affects capital, scheduling flexibility, and validation approach. Single-use dominates clinical and early commercial supply (2,000L single-use is now the norm) — faster changeover, no cleaning validation, lower capex, and better multi-product capacity utilization. Stainless steel remains dominant at true commercial scale (10,000L+ for high-volume products like Humira/adalimumab), where the capex is justified by predictable multi-year campaigns. Some CDMOs have converted entirely to single-use (Samsung Biologics Plant 4 is 8×15,000L stainless, but their Plant 5 is single-use focused); others operate hybrid facilities. Sponsors should match their product's projected annual demand to the CDMO's most economically appropriate architecture — asking a stainless steel CDMO to run at 2,000L will typically cost more than an SUB-optimized site.
How to structure a biologics CDMO RFP — a 6-step buyer framework
For sponsors running competitive biologics CDMO selection: 1. Expression platform + cell line strategy — CHO, HEK, or microbial; CDMO's own cell line vs your cell line; typical titer benchmarks at bioreactor scale. 2. Scale ladder — validated bioreactor scale that matches your intended clinical and commercial demand (2,000L single-use is standard clinical; 15,000L stainless is standard commercial for high-volume mAbs). 3. Quality track record — FDA inspection classifications on the specific facility slated for your program (see ranked table above), Warning Letter history, EMA/MHRA GMP certificate density. 4. Downstream process — standard Protein A + polish sufficient, or does your product need extended purification for aggregate/impurity control. 5. Fill-finish integration — same site, same CDMO group, or coordinated separately (affects timelines and comparability). 6. Financial stability — parent-company health matters for biologics because commercial engagements are 3-5 year commitments; SEC filings and M&A activity indicate reliability. The methodology page explains how these factor into Signal Score.
Biologics / mAb CDMOs — Frequently Asked Questions
Who are the top Biologics / mAb CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Biologics / mAb CDMOs include Pfizer CentreOne, Merck KGaA / MilliporeSigma (CDMO), FUJIFILM Diosynth Biotechnologies. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Biologics / mAb CDMOs have FDA inspection records?
CDMO Signal tracks 15 Biologics / mAb CDMOs with FDA inspection records and 143 EMA/MHRA GMP certificates across the group.
What should I look for in a biologics CDMO?
Match bioreactor scale and modality (mAb, bispecific, fusion protein) to your program, confirm cell-line and process-development support, and prioritize a clean FDA and EMA/MHRA record at the scale you'll commercialize at.
What is the difference between a biologics CDMO and a cell or gene therapy CDMO?
Biologics CDMOs make large molecules (antibodies, proteins) in bioreactors at litre-to-thousands-of-litre scale. Cell and gene therapy CDMOs make living cells or viral vectors in much smaller, often per-patient batches under different containment and analytics.
Related modalities